← Back to Clinical Trials
Recruiting NCT02250352

NCT02250352 Core Biopsies for Establishing a Breast Tumor Tissue Repository

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02250352
Status Recruiting
Phase
Sponsor University of Southern California
Condition Breast Cancer
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2013-11-14
Primary Completion 2026-11-14

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
cytology specimen collection procedure

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2013-11-14 with a primary completion date of 2026-11-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research trial establishes a breast tumor tissue repository from core biopsies. Collecting breast tissue from core biopsies may allow doctors to learn more about the biology of breast cancer and to analyze proteins, genes, and other components of tumor cells. It may also allow doctors to conduct future studies to help understand how breast cancer grows and how it responds to different types of therapy. This will help doctors develop better breast cancer therapies and better tests to help make treatment decisions.

Eligibility Criteria

Inclusion Criteria: * Known or suspected breast cancer * Known or suspected metastatic solid tumor that originated in the breast per the patient's medical history Exclusion Criteria: * Inability to sign informed consent * Known bleeding disorder * Use of anticoagulant medications (heparin, warfarin, etc.) within one week prior to biopsy * Use of antiplatelet medications (aspirin, clopidogrel, etc.) within one week prior to biopsy

Contact & Investigator

Central Contact

Zeno Ashai

✉ zeno.ashai@med.usc.edu

📞 323-865-0463

Principal Investigator

Evanthia Roussos-Torres, M.D.

PRINCIPAL INVESTIGATOR

University of Southern California

Frequently Asked Questions

Who can join the NCT02250352 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02250352 currently recruiting?

Yes, NCT02250352 is actively recruiting participants. Contact the research team at zeno.ashai@med.usc.edu for enrollment information.

Where is the NCT02250352 trial being conducted?

This trial is being conducted at Los Angeles, United States.

Who is sponsoring the NCT02250352 clinical trial?

NCT02250352 is sponsored by University of Southern California. The principal investigator is Evanthia Roussos-Torres, M.D. at University of Southern California. The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology